At a glance
- Originator Shire Pharmaceuticals Group
- Developer GSK; Shire Pharmaceuticals Group
- Class Anthracyclines; Cytostatic antibiotics
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 06 Dec 2000 Profile reviewed but no significant changes made
- 23 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)